Currently we test and support the following browsers:
Please note that this is not intended to be an exhaustive list of browsers that support web standards, nor a test of browser compliance, nor a side-by-side comparison of various manufacturers’ browsers.
Leukemias / Lymphomas : Acute lymphoblastic leukemia
Acute lymphoblastic leukemia (ALL) in children presents a significant challenge, particularly when relapses occur very early (within 18 months from initial diagnosis), or in cases of second or greater recurrence. Patients who experience a relapse of ALL or who don’t achieve a remission have a poor outcome.
This study uses a new agent called EZN-3042 which targets survivin, a protein expressed in leukemia cells at relapse that promotes the leukemia cells to grow. Several survivin antagonists [a drug that counteracts, blocks, or abolishes the action of a gene or protein] have been developed for clinical use. The duration of the study will be for 2 years.
This study anticipates that the new investigational drug EZN-3042 will be safe and tolerable when given both alone and in combination with standard chemotherapy drug.
The goal of this phase I study is to find out the dose of EZN-3042 that can be safely given without serious side effects both alone and in combination with standard chemotherapy drugs during re-induction.
For the current eligibility status of this clinical study, referring physicians must contact St. Jude Children's Research Hospital at 1-866-2ST-JUDE (1-866-278-5833).
Deepa Bhojwani, MD
St. Jude Children’s Research Hospital
262 Danny Thomas Place
Memphis, TN 38105 USA
Voice: 1-866-2ST-JUDE (1-866-278-5833)
Referring or consulting physicians only: email@example.com
For all other inquiries about St. Jude Children's Research Hospital studies: firstname.lastname@example.org
The above information is intended to provide only a basic description about a research protocol that may be currently active at St. Jude. The details made available here may not be the most up-to-date information on protocols used by St. Jude. To receive full details about a protocol and its status and or use at St. Jude, a physician must contact St. Jude directly.